Backwards & Forwards: ADC Therapy for mBC

Target Audience

The educational design of this activity addresses identified knowledge and practice gaps among medical oncologists, radiation oncologists, surgical oncologists, and oncology nurses, nurse practitioners (NPs), and physician assistants/associates (PAs), in a position to manage patients with metastatic breast cancer (mBC).

Program Overview

Breast cancer (BC) is the second most frequent cancer in the world and the leading cause of cancer mortality in women.  Although more than 80% of BC cases are early stage at diagnosis, approximately 5% present with incurable metastatic BC (mBC). Even after completion of curative-intent treatment, 15% to 25% of patients ultimately develop mBC, which has a low 5-year survival rate. Antibody-drug conjugates (ADCs) are a newer class of therapies that have shown great potential in treatment of mBC. This is particularly true in patients with metastatic triple-negative breast cancer (mTNBC), which has an aggressive course and poor prognosis, and the newer classification of hormone receptor positive (HR+) human epidermal growth factor receptor 2 (HER2)-low and -ultralow breast cancer. 

This engaging educational activity provides concise and practical information in a coffee-talk style format. Included in this program are a 3D animation detailing the mechanisms of action of ADCs as well as an examination of ADC efficacy and safety in patients with mTNBC and HR+HER2-negative, -low, and ultralow BC. Other topics include the role of ADCs in treatment of patients with mBC and brain metastases, prevention and management of treatment emergent adverse events (TEAEs) associated with ADCs, and an overview of the most recent data on ADCs from the European Society of Medical Oncology Congress 2024. 

Educational Objectives 

After completing this activity, the participant should be better able to:

• Discuss the indications and mechanisms of action of ADC therapies approved for mBC
• Summarize pivotal clinical trial findings supporting current indications for ADC therapies in mBC
• Select optimal ADC therapy for an individual patient with mBC based on patient and disease characteristics, treatment history, and biomarker testing
• Develop strategies to identify and manage TEAEs associated with ADCs
• Analyze approaches to implementation of new findings and therapeutic options in mBC, emerging from recent hematology/oncology conferences

Physician Accreditation Statement

Integritas Communications is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physician Credit Designation

Integritas designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The ANCC’s Commission on Accreditation recognizes educational activities that are approved for AMA PRA Category 1 Credits™ by providers who are accredited by the ACCME to award credit to learners. This reciprocity agreement allows nurses and nurse practitioners to use AMA PRA Category 1 Credits™ as approved ANCC contact hours for license renewal. 

Disclosures of Relevant Financial Relationships

Integritas adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content are required to disclose all financial relationships with any ineligible company within the past 24 months to Integritas.  All financial relationships reported are identified as relevant and mitigated by Integritas in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Integritas to assure objectivity and that the activity is free of commercial bias. 

All relevant financial relationships have been mitigated. 

The faculty has the following relevant financial relationships with ineligible companies:

Joyce A. O’Shaughnessy, MD: Consulting Fees: Agendia Inc., Aptitude Health, AstraZeneca plc, Byondis B.V., Caris Life Sciences, BioNTech SE, Daiichi Sankyo, Inc., DAVA Oncology LP, Eisai Inc., Exact Sciences Corp., F. Hoffmann-La Roche Ltd, Fishawack Health, G1 Therapeutics, Inc., Guardant Health, Inc., Genentech, Inc., Gilead Sciences, Inc., Eli Lilly and Company, Loxo Oncology, Inc., Menarini Group/ Stemline Therapeutics, Merck & Co., Inc., Mersana Therapeutics Inc., Novartis AG, Ontada LLC, Pfizer Inc., Pierre Fabre Pharmaceuticals, Puma Biotechnology, Inc., Samsung Bioepis Co., Ltd, Sanofi, Seagen Inc., Stemline Therapeutics, Inc., Tempus AI, Inc., Veru Inc.

The planners and managers at Integritas Communications have no relevant financial relationships to disclose.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Integritas Communications does not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Instructions to Receive Credit

In order to receive credit for this activity, the participant must score 70% on the posttest and complete the program evaluation.

Fee Information & Refund/Cancellation Policy

There is no fee for this educational activity.

Integritas Contact Information

For questions about this activity, please contact Integritas Communications at info@exchangecme.com.